They emphasized that in liver cancer the inhibitors against DNA methyltransferase increased interferons and activated T cells, while the inhibitors against histone methyltransferase increased UL16 binding protein 1 (ULBP1) and activated natural killer cells. Here, PRDM9 is linked to liver cancer.